Single agent IMC-225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that express the epidermal growth factor receptor (EGF-R). - Saltz,L.; Meropol,N.J.; Loehrer,P.J. (Proc Am Soc Clin Oncol, 2002)